Lanreotide + Placebo (for sunitinib) + Sunitinib
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoid Tumors
Conditions
Carcinoid Tumors
Trial Timeline
Jan 7, 2013 → Dec 1, 2017
NCT ID
NCT01731925About Lanreotide + Placebo (for sunitinib) + Sunitinib
Lanreotide + Placebo (for sunitinib) + Sunitinib is a phase 2 stage product being developed by Pfizer for Carcinoid Tumors. The current trial status is unknown. This product is registered under clinical trial identifier NCT01731925. Target conditions include Carcinoid Tumors.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01731925 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Carcinoid Tumors